The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed reports circulating on social media claiming that Camosunate, an antimalarial drug, has been banned in Nigeria.
The agency clarified that it has never banned Camosunate or any medicine containing the artesunate-amodiaquine combination, describing the circulating reports as false and misleading.
NAFDAC, however, acknowledged that some of the symptoms mentioned in the viral reports could be associated with known side effects of the drug. These include nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite.
The agency urged members of the public and healthcare professionals to report any suspected adverse reactions to medicines for proper investigation and assessment.
According to NAFDAC, such reports can be submitted through the NAFDAC Med Safety App, available for download on Android and iOS devices, or at the nearest NAFDAC office.
The agency also appealed to Nigerians to stop sharing the unverified information, warning that the spread of misinformation could create unnecessary public anxiety.
It further encouraged individuals who had already circulated the claim to share the agency’s clarification through the same social media platforms to help correct the misinformation.
The clarification was issued by the Director-General of NAFDAC, Professor Mojisola Adeyeye.

